Is it possible to reduce total risk of hypertension? Review article
Article Sidebar
Published:
Mar 31, 2012
Keywords:
hypertension, global risk, class effect, ACE-i, diuretics, Ca-blokers, angiotensin receptor blockers – ARB, perindopril
Main Article Content
Abstract
Hypertension leads to serious clinical problems and thus is one of the leading causes of death even in countries with low income. Nowadays we should estimate the total risk of hypertension and decide how to treat our patients. Trials provided on rules of evidence based medicine are the best way to acquire knowledge witch treatment is the best choice. As we learn more and more about efficiency of antihypertension drugs, we have a lot of doubts, so specialist are trying to give us some simple scheme of treatment. It seems that using a combination of two from: thiazide like diuretics, ACE-i or Ca-blockers are the goal. But we also know that we should give up the way of thinking that there is a simple class effects of these drugs. Some of them especially perindopril looks very promising because of its unique pharmacokinetics and rather the strongest evidence of reducing global risk of hypertension.
Article Details
How to Cite
Rawdanowicz , J., & Kuch , M. (2012). Is it possible to reduce total risk of hypertension?. Medycyna Faktow (J EBM), 5(1(14), 19-27. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2474
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Lewington S., Clarke R., Qizilbash N. et al.; Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360(9349): 1903-13.
2. Wright J.M., Musini V.M.: First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009; Issue 3.
3. Brewster L.L., Kleijnen J., van Montfrans G.A.: Withdrawn: Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. Cochrane Database of Systematic Reviews 2005.
4. Chen N., Zhou M., Yang M. et al.: Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews 2010; Issue 8.
5. Turnbull F.; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
6. Al Khalaf M.M., Thalib L., Doi S.A.: Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. Am. J. Cardiovasc. Drugs 2009; 9(1): 29-43.
7. Arguedas J.A., Perez M.I., Wright J.M.: Treatment blood pressure targets for hypertension. Cochrane Database of Systematic Reviews 2009; Issue 3.
8. Musini V.M., Tejani A.M., Bassett K., Wright J.M.: Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 2009; Issue 4.
9. Verdecchia P., Reboldi G., Angeli F. et al.: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
10. Brugts J.J., Ninomiya T., Boersma E. et al.: The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur. Heart J. 2009 Jun; 30(11): 1385-94.
11. Tan K.W., Leenen F.H.H.: Persistence of anti-hypertensive effect after missed dose of perindopril. Br. J. Clin. Pharmacol. 1999; 48(4): 628-630.
12. Tsoukas G., Anand S., Yang K.; CONFIDENCE Investigators: Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am. J. Cardiovasc. Drugs 2011; 11(1): 45-55.
13. Januszewicz A., Januszewicz W., Rużyłło W.: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005.
14. Rodriguez-Granillo G.A., Vos J., Bruining N. et al.; Investigators of the EUROPA Study: Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study. Am. J. Cardiol. 2007 Jul 15; 100(2): 159-63.
15. Bruining N., de Winter S., Roelandt J.R. et al.; EUROPA/PERSPECTIVE Investigators: Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron. Artery Dis. 2009 Sep; 20(6): 409-14.
16. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 2004 Jul 20; 141(2): 102-12.
17. Bangalore S., Kumar S., Messerli F.H.: Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Phycians’ Desk Reference. Am. J. Med. 2010; 123: 1016-1030.
2. Wright J.M., Musini V.M.: First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009; Issue 3.
3. Brewster L.L., Kleijnen J., van Montfrans G.A.: Withdrawn: Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. Cochrane Database of Systematic Reviews 2005.
4. Chen N., Zhou M., Yang M. et al.: Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews 2010; Issue 8.
5. Turnbull F.; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
6. Al Khalaf M.M., Thalib L., Doi S.A.: Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. Am. J. Cardiovasc. Drugs 2009; 9(1): 29-43.
7. Arguedas J.A., Perez M.I., Wright J.M.: Treatment blood pressure targets for hypertension. Cochrane Database of Systematic Reviews 2009; Issue 3.
8. Musini V.M., Tejani A.M., Bassett K., Wright J.M.: Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 2009; Issue 4.
9. Verdecchia P., Reboldi G., Angeli F. et al.: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
10. Brugts J.J., Ninomiya T., Boersma E. et al.: The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur. Heart J. 2009 Jun; 30(11): 1385-94.
11. Tan K.W., Leenen F.H.H.: Persistence of anti-hypertensive effect after missed dose of perindopril. Br. J. Clin. Pharmacol. 1999; 48(4): 628-630.
12. Tsoukas G., Anand S., Yang K.; CONFIDENCE Investigators: Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am. J. Cardiovasc. Drugs 2011; 11(1): 45-55.
13. Januszewicz A., Januszewicz W., Rużyłło W.: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005.
14. Rodriguez-Granillo G.A., Vos J., Bruining N. et al.; Investigators of the EUROPA Study: Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study. Am. J. Cardiol. 2007 Jul 15; 100(2): 159-63.
15. Bruining N., de Winter S., Roelandt J.R. et al.; EUROPA/PERSPECTIVE Investigators: Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron. Artery Dis. 2009 Sep; 20(6): 409-14.
16. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 2004 Jul 20; 141(2): 102-12.
17. Bangalore S., Kumar S., Messerli F.H.: Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Phycians’ Desk Reference. Am. J. Med. 2010; 123: 1016-1030.